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Abstract
Background: In the last 20 years routine T CD4+ lymphocyte (CD4+) cell count has proved to be a key factor to
determine the stage of HIV infection and start or discontinue of prophylaxis for opportunistic infections. However,
several studies recently showed that in stable patients on cART a quarterly CD4+ cell count monitoring results in
limited (or null) clinical relevance. The research is intended to investigate whether performing quarterly CD4+ cell
counts in stable HIV-1 patients is still recommendable and to provide a forecast of the cost saving that could be
achieved by reducing CD4+ monitoring in such a category of patients.
Methods: The study is based on data referring to all HIV-infected patients > 18 years of age being treated at two
large infectious diseases units located in the metropolitan area of Genoa, Italy. The probability of CD4+ cell counts
dropping below a threshold value set at 350 cells/mm3 is assessed using confidence intervals and Kaplan-Meier
survival estimates, whereas multivariate Cox analysis and logistic regression are implemented in order to identify
factors associated with CD4+ cell count falls below 350 cells/mm3.
Results: Statistical analysis reveals that among stable patients the probability of maintaining CD4+ >350 cell/mm3 is
more than 98%. Econometric models indicate that HCV co-infection and HIV-RNA values >50 copies/mL in previous
examinations are associated with CD4+ falls below 350 cells/mm3. Moreover, results suggest that the cost saving that
could be obtained by reducing CD4+ examinations ranges from 33 to 67%.
Conclusions: Empirical findings shows that patients defined as stable at enrollment are highly unlikely to experience a
CD4+ value <350 cell/mm3 in the space/arc of a year. The research supports a recommendation for annual CD4+
monitoring in stable HIV-1 patients.
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Background
CD4+ T lymphocyte (CD4+) cell count monitoring is
playing a crucial role as a surrogate marker of the im-
mune system function in the clinical management of
Human Immunodeficiency Virus (HIV) infection [1–3].
In the last 20 years, routine CD4+ cell counts, in com-
bination with HIV-RNA copies counts [4], have proved
to be the best predictors of therapy effectiveness and
probability of disease progression [5–7]. Consistently
with these findings, both the World Health Organization
(WHO) and the United States Department of Health
and Human Services (DHHS) recommend HIV-RNA as
the most valuable marker of combined antiretroviral
therapy (cART) efficacy [8, 9]. Indeed, CD4+ cell count
is still a key factor in determining the stage of HIV infec-
tion [9] and plays a role in guiding clinical care to start
or discontinue the prophylaxis for opportunistic infec-
tions [10]. It is widely accepted by the scientific commu-
nity that the risk of onset of opportunistic infection
increases considerably as the CD4+ falls below 350 cells/
mm3 [11], even if the primary prophylaxis starts at 200
cells/mm3 [12–14]. However, in patients on cART with
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CD4+ >200 cell/mm3 and HIV-RNA <50 copies/mL,
several studies have shown that quarterly CD4+ cell
count monitoring results in limited (or null) clinical
relevance [15–23] and so a less frequent (e.g. yearly)
CD4+ monitoring strategy has been proposed for this
patient category. A reduction in the frequency of CD4+
cell counts could lead to considerable financial savings.
A recent study [24], estimated that the adoption of a
once per year CD4+ monitoring strategy for all patients
with HIV-RNA <50 copies/mL in the United States
could result in annual savings of 10.2 million United
States dollars (USD). A similar study, carried out in
Australia outlined potential financial savings of 1.4 mil-
lion (USD) by adopting the once a year CD4+ monitor-
ing strategy for all the eligible Australian patients with
HIV infection [21].
In this paper we report the results of a retrospective
observational study in a cohort of HIV-infected patients
with the objective to show how often, in virologically
suppressed patients, a decrease CD4+ cell count was ob-
served and, therefore, if performing quarterly CD4+
counts is still recommendable.
Methods
This was a retrospective, longitudinal, multicenter ana-
lysis of 1771 HIV-infected patients followed in two large
infectious diseases units located in the metropolitan area
of Genoa (Liguria Region), Italy.
Patients are enrolled in the RETE LIGURE HIV data-
base after giving informed consent to provide their data
for academic no profit studies, (Ethical Committee
Liguria Region, August 28, 2013). The data include
demographics (age, gender, nationality), hepatitis C virus
(HCV) - co-infection (defined as HCV-antibody positiv-
ity) risk factors for HIV infection, time since HIV infec-
tion and both HIV-RNA and CD4+ cell count status. All
data were collected through a web-based platform
(www.reteligureHIV.it).
Eligible patients for the study were HIV-infected
adults, with HIV-RNA <50 copies/mL and CD4+ >500
cell/mm3 throughout 2011. These patients, defined as
“stable patients”, were included in the study and ob-
served during a 1-year time period, from January to De-
cember 2012.
The primary endpoint was investigating whether there
was any significant change in CD4+ cell counts in stable
patients. Since HIV-RNA <50 copies/mL leads to rises in
CD4+ cell counts and improved survival, particularly if
the CD4+ cell count has risen above 350 cells/mm3 [25],
the value of 350 cells/mm3 was set as the threshold [26].
According to previous studies [16], confidence inter-
vals and Kaplan-Meier survival estimates were imple-
mented and the probability of the CD4+ cell count
dropping below the threshold value was assessed.
Moreover, a multivariate Cox analysis and a logistic re-
gression were used in order to identify factors associated
with CD4+ cell count falls below the threshold value of
350 cells/mm3.
A forecast of the savings that could be achieved by re-
ducing CD4+ monitoring in stable patients was finally
provided. The economic consequences of less frequent
CD4+ cell counts were estimated assuming two alterna-
tive scenarios: in the first one it was assumed that all
stable patients were monitored once annually, while in
the second model stable patients were divided on the
basis of the results of the econometric analysis and it
was hypothesized CD4+ cell counts twice a year for
those patients characterized by higher risk of CD4+ de-
clines below 350 cells/mm3. Referring to the national
context, the total number of patients on cART was esti-
mated according to Raimondo et al. [27].
The cost of each examination was computed using the
official tariff established by the Italian Ministry of Health
for CD4+ tests (€ 17.09 per test).
Results
A total of 372 patients (21% of the entire cohort) met
the inclusion criteria for study entry. The mean age was
51 years old, 61% of patients were male and 88% were
Italians; the majority (73%) had been infected with HIV
for more than 10 years, and 34% were HCV antibody
positive (the demographic characteristics of the study
population are shown in Table 1). During 2012 the mean
number of CD4+ cell counts per patient was 2.7 with,
on average, one examination every 107 days. During the
period of observation, 7 out of 372 (1.88%) total stable
HIV-infected patients showed CD4+ cell count values
falling below 350 cells/mm3; on average, a CD4+ cell
count value below 350 cells/mm3 was observed after
285 days (the first occurred after 51 days, while the last
after 359 days). In details we registered two virological
failures, three patients were treated with PEG-interferon
and ribavirin, while two patients have a transient drop
with complete recovery in the next control.
Statistically significant differences in the frequency of
CD4+ tests by age (<45 versus 45–65 and 65+, p = 0.01
and p = 0.003 respectively) and transmission risk (drug
addiction versus other risk factors, p = 0.02) were de-
tected by means of Kruskal-Wallis tests.
Table 2 provides the 95% binomial proportion confi-
dence interval for the CD4+ count to fall below 350
cells/mm3: the probability of experiencing a CD4+ fall
below 350 cells/mm3 ranges from 0.76 to 3.8%. When
data were analyzed by HCV co-infection, it was noted
that 1.2% (95%CI, 0.002–0.03) of non HCV co-infected
patients had CD4+ values below 350 cells/mm3 in the
arc of a year, while the percentage increased to 3.2% with
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reference to HCV co-infected patients (i.e. patients with
HCV antibody positive) (95% CI, 0.01–0.08).
As shown by the Kaplan-Meier survival estimates
(Fig. 1), the probability of maintaining CD4+ ≥ 350 cells/
mm3 was higher for patients without HCV co-infection
(d_hcv = 0) rather than for those with co-infection
(d_hcv = 1). Moreover, the data pointed out differences
between the two groups of patients also with reference
to the timing of CD4+ falls: on average, the CD4+ cell
count value declines below 350 cells/mm3 in HCV co-
infected patients occurred in 134 days, while in non-
HCV in 285 days.
Results of the Cox regression (Table 3) suggested that
CD4+ cell count value < 350 cells/mm3 was strongly de-
fined (hazard ratio = 15.4) by HCV co-infection and
HIV-RNA values > 50 copies/mL in the previous examin-
ation (hazard ratio = 5.95). The probability of having
CD4+ < 350 cells/mm3 also seemed to be associated with
being an injection drug user (hazard ratio = 0.03), a vari-
able positively correlated with HCV co-infection (correl-
ation index = 0.82), whereas the gender, age and time
since HIV infection was detected did not seem to be de-
terminant of CD4+ falling below 350 cells/mm3. These
results were also confirmed by logistic regression
(Table 3). HCV co-infection (Coef. = 2.2) and HIV-RNA
values > 50 copies/mL in the previous examination
(Coef. = 2.1) increased the probability of having CD4+
count value < 350 cells/mm3, while other variables did
not impact significantly on CD4+ values.
In 2012 the total number of CD4+ cell counts among
stable patients was 1002 and the global average of the
CD4+ measurements was 2.7. The cost saving that could
be obtained by reducing CD4+ examinations ranges
from 33 to 67%.
The analysis demonstrated that if CD4+ monitoring of
all stable patients was limited to once annually, 630 CD4
+ measurements could be eliminated and the total an-
nual expenditure for CD4+ examination could be re-
duced by 63% (1st scenario). Furthermore, if CD4+
monitoring was limited to once annually in patients
without HCV co-infection and twice annually in patients
with co-infection, 506 CD4+ measurements could be cut
and the total annual expenditure for CD4+ examinations
could decrease by 50% (2nd scenario). Moreover, com-
pared with CD4+ frequency recommended by HIV anti-
retroviral Italian Guidelines (two or three times a year),
the total cost saving could be 67% or 50% respectively in
the first scenario, and 56% or 33% in the second one.
Table 4 reports the forecast of the impact of less fre-
quent CD4+ monitoring of stable patients in the Italian
context assuming the two alternative scenarios. The total
cost saving is computed hypothesizing both the CD4+
frequency recommended by HIV antiretroviral Italian
Guidelines (two or three times a year – column A and
C) and the global average of CD4+ tests occurred in
2012 (column B). The results show that the reduction of
CD4+ examinations could bring significant savings in
economic resources, with values ranging from about €
200.000 to € 600.000.
Discussion
The analysis suggests that yearly CD4+ monitoring in
stable patients could be more appropriate.
During the period of observations none of the patients
reached the critical value of 200 cells/mm3, which is
usually considered as the threshold under which to start
a prophylaxis against opportunistic infections (such as
Pneumocystis jirovecii pneumonia) and no change in the
therapies drawn by CD4+ cell count declines alone has
been made in the study population. Furthermore, among
the seven patients who fell below the threshold value, 6
Table 2 95% Confidence Interval of binomial variable CD4 < 350
Variable Obs Mean Std. Err. – Binomial Exact –
[95% Conf. Interval]
CD4 < 350 371 .0188679 .0070638 .0076187 .0384872
Table 1 Demographic and clinical characteristics of HIV-infected
patients with HIV-RNA <50 copie/mL and CD4 > 500 cell/mm3
Patients %
Age
< 45 72 19%
45–65 278 74%
65 + 26 7%
Gender
Male 229 61%
Female 147 39%
Nationality
Italian 329 88%
Other 47 12%
HCV co-infection
Positive 126 34%
Negative 250 66%
Time since HIV infection (years)
< 5 22 6%
5–10 79 21%
> 10 275 73%
Risk Factor
Heterosexual 152 40%
IDU (a) 121 32%
MSM (b) 61 16%
Other 42 11%
(a) MSM men who have sex with men; (b) IDU injection drug users
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rose again above 350 cells/mm3 in the next CD4+ cell
count evaluation, and only one needed two rounds of tests
before his CD4+ cell count was back above the threshold.
Consequently, the hypothesis of a less frequent monitor-
ing of CD4+ cell counts would not have had any conse-
quence in terms of patient prognosis and therapies.
Indeed, an additional assurance for patient health is
the preservation of HIV-RNA evaluation 3/4 times a
year. An increase in HIV-RNA load may certainly repre-
sent a sort of “alarm bell” which strongly suggests a viro-
logical failure and, consequently, an immunological
failure. HIV-RNA is the key factor in guiding therapy
optimization: in patients with HIV-RNA <50 copies/mL
HIV infection is unlikely to advance and the treatment
does not require any change based on the one time re-
duction of CD4+ cell counts.
Our results probably underestimate the number of pa-
tients that could be monitored once a year: firstly, in our
analysis we defined strict inclusion criteria for study
entry and we set a threshold value at 350 cell/mm3,
whereas previous research considered all patients with
viral suppression and investigated the probability of CD4
+ dropping below 200 cell/mm3; secondly, it is expected
that in the near future the number of stable patients will
increase, due to the new cART regimens, based on anti-
retroviral highly efficacy and better tolerated [28].
In this experience inclusion criteria were based only on
immune-virological data and were independent from pre-
vious AIDS diagnosis and demographical or social vari-
ables. As a consequence, the results might be applicable to
all patients who met the study criteria to define “stable”.
However, a more frequent monitoring might be indicated
also in these patients in case of changes in the clinical sta-
tus or in case of concomitant treatments that could cause
a CD4 + count reduction. Of note, the recent guidelines of
Department of Health and Human Services [9], in patients
who have been on cART since at 2 years, with HIV-RNA
consistently suppressed, counsel to monitor CD4+ count
yearly when CD4+ count is above 300 cells/mm3, or even
not to monitor CD4+ count at all in patients with more
Fig. 1 Kaplan-Meier survival estimates
Table 3 Cox regression and logit regression
Variable Cox regression Logit regression
Hazard Ratio Coefficient
Gender (1 = F) .1764862 (0.143) −1.728616 (0.159)
Age .9883046 (0.749) −.0174055 (0.649)
Dummy MSM (a) .9057002 (0.934) .0500618 (0.966)
Dummy IDU (b) .035092 (0.005)*** −3.120108 (0.017)**
Dummy HCV co-infection 15.43625 (0.008)*** 2.24666 (0.033)**
Time since HIV infection
(years)
.9997115 (0.194) −.0003251 (0.141)
HIV RNA load > 50 in previous
tests
5.951844 (0.070)* 2.154811 (0.032)**
Constant – 8.310305 (0.296)
Log likehood =
−28.6398
Log likelihood =
−27.0727
Prob. chi2 = 0.0336 Prob. chi2 = 0.0323
(a) MSM men who have sex with men; (b) IDU injection drug users
* p < 0.1
** p < 0.05
*** p < 0.01
Table 4 Economic consequences of less frequent CD4
monitoring in Italy
Column A
CD4 2 times/
year
Column B
CD4 2.7 times/
year
Column C
CD4 3 times/
year
Total cost € 594.428 € 799.506 € 891.642
Cost saving (1st scenario) € 297.214 € 502.292 € 594.428
Cost saving (2nd scenario) € 198.143 € 403.220 € 495.357
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than 500 CD4+ cells/mm3 (grade of recommendation
CIII). According to our experience the crucial issues is the
immunological “stability”, regardless the route of acquisi-
tion or the nadir cd4 count.
Conclusions
The results of the statistical analysis reveal that among
stable patients the probability of maintaining CD4+
>350 cell/mm3 was more than 98% and suggest that
yearly CD4+ monitoring in this category of patients
could be more appropriate.
Econometric models indicate that HCV co-infection
and HIV-RNA load >50 copies/mL in previous examina-
tions were associated with CD4+ falls below 350 cells/
mm3. However, our data demonstrated that the risk of
CD4+ cell count falling below 350 cell/mm3 was very
low also in this scenario, as only 3.2% of the HCV co-
infected patients had CD4+ values below 350 cells/mm3
in the space of a year.
Reduced CD4+ examinations would provide a signifi-
cant cost saving: if all stable patients were monitored
once per year, the total expenditure would be reduced
by 63%, whereas it would be decreased by 50% by moni-
toring stable patients without HCV annually and those
with HCV co-infection twice a year.
In conclusion, our results straighten the recommenda-
tion of reducing the frequency of CD4+ monitoring in
stable patients highlighted by national and international
guidelines, as this strategy revealed a potential cost-
saving.
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